The EU Biosimilar industry, which is central to competitiveness, needs Ambitious, Coherent, & Competition-Driven Biotech Policies

Parliament SANT Committee vote takes the high road on medicines security in Critical Medicines Act Report

The Safe Hearts Plan should improve access to affordable innovation and better treatment for all patients

Pharma legislation deal important for the future EU pharmaceutical industry but most importantly for access to medicine

Environment omnibus and impact study fail to address huge flaws in Urban waste water treatment directive

Biosimilars 2025: A Turning Point for equitable access and EU competitiveness

European study shows falling prices, rising costs and shortages – findings released during World AMR Awareness Week

Healthcare Associations warn of risks from PFAS restriction approach – Failure to assess the impact on the availability of human and animal medicines

European Commission risks repeating past mistakes in Urban Wastewater Treatment Directive cost study

Industry unites for a bold Critical Medicines Act that prioritises secure supply of medicines for patients